(Q45348765)

13 December 2017

title

Strategies for optimizing bacillus Calmette-Guérin (English)

1 reference

13 December 2017

Jay B Shah

1

1 reference

13 December 2017

Ashish M Kamat

series ordinal

2

1 reference

13 December 2017

publication date

27 February 2013

1 reference

Urologic Clinics of North America

13 December 2017

published in

1 reference

13 December 2017

volume

40

1 reference

13 December 2017

issue

2

1 reference

13 December 2017

page(s)

211-218

1 reference

Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Immunization and MS: a summary of published evidence and recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

BCG vaccine-induced neuroprotection in a mouse model of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and [...]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Intravesical bacille Calmette-Guérin therapy for muscle invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Impact of a second transurethral resection on the staging of T1 bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Prostatic urothelial carcinoma: is transurethral prostatectomy necessary before bacillus Calmette-Guérin immunotherapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Bladder cancer in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Variation in protection by BCG: implications of and for heterologous immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Use of statins and outcome of BCG treatment for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Intravesical bacille Calmette-Guérin therapy for non-muscle-invasive bladder cancer: effects of concurrent statin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of mainte

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

BCG intravesical instillations: recommendations for side-effects management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guérin-induced toxicity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist?. analysis of a quarter century of literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Prognostic value of Bcl-2 and Bax tumor cell expression in patients with non muscle-invasive bladder cancer receiving bacillus Calmette-Guerin immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

Predictive biomarkers of bacillus calmette-guérin immunotherapy response in bladder cancer: where are we now?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.012

10.1016/J.UCL.2013.01.012

7 January 2021

Identifiers

DOI

1 reference

13 December 2017

1 reference